Add like
Add dislike
Add to saved papers

A comparative clinical study on role of 5-flurouracil versus triamcinolone in the treatment of keloids.

A wide range of therapies exist for keloids. But despite the multiple treatment modalities available, keloids still remain a significant challenge for both the clinician and the patient. To compare the efficacy of 5-flurouracil (5-FU) versus triamcinolone as a therapeutic agent for the treatment of keloids. A randomized control trial was carried out at a teaching hospital in Kolkata over a period 2.5 years. Forty-four patients took part in the study, 20 in group F and 24 in group T. The age ranged from 16 to 66 years. The mean age of group F was 34.7 ± 11.0124 years (range 16-66 years) and of group T was 32.96 ± 9.584 years (range 19-60 years). The difference in the age and sex between the two groups was comparable and not statistically significant (p = 0.096). The response was rated as excellent (76-100% decrease in volume), good (51-75%), fair (26-50%), and poor (less than 25%). The reduction in keloid volume was comparable in both the groups. But side effects were much more in group F compared to group T. About 95% of the patients in group F found the injection very painful. About 6% of the patients in group F presented soon after the first two to three sessions with superficial ulcerations at the injection site accompanied by mild discomfort and discharge. This side effect was not seen in group T. Regarding pain at the injection site and superficial ulceration, the difference between the two groups was found to be statistically significant (p < 0.05). The patients treated with 5-FU experienced side effects such as hyperpigmentation, pain at the injection site, and superficial ulceration, which were statistically highly significant. It appears from this study that triamcinolone is a better tolerated and less toxic alternative to 5-FU in the management of keloids.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app